Skip to main content

Investor Relations

IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from our targeted therapies.

Investor Presentation
Recent News
Jul 11, 2024

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the closing of its underwritten public offering of 8,355,714 shares of its common stock at a public offering price of $35.00 per share,...

Jul 9, 2024

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants. IDEAYA is selling 7,228,572 shares of common stock...

Jul 9, 2024

IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $200.0 million of shares of its common stock and, in lieu of common stock, to offer and sell to...

All Releases

Monday, July 8, 2024
8:00am EDT

Pre-registration is available through the following link:

Monday, June 10, 2024
8:00am - 9:00am EDT

Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Corinne (Jenkins) Johnson, Vice President, Equity Research, Biotechnology

All Events

Stock Info

Stock Information

Investor Contact

Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations

Subscribe to email alerts
* Required Fields

Improving Lives Through Transformative Precision Medicines

Close Menu